The Credibility Filter Wall Street Uses to Sort Biotech Winners
Stoke Therapeutics, Inc. (STOK)
Last stoke therapeutics, inc. earnings: 11/12 08:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
VANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a median of $287.5 million each; and nearly every one of them carried mid or late stage clinical data[1]. That is not a coincidence. The IQVIA Institute's latest annual report found that biopharma dealmaking is now clustering around high value science and companies with credentialed pipelines[2]. It’s becoming apparent that smart money is no longer chasing press releases, it’s chasing invitations. Conference stage presentations from field defining researchers, peer reviewed journal publications, and stacked regulatory designations have become the filters that separate credible programs from noise. Five names in today's coverage are earning exactly that kind of recognition: Avaí Bio (OTCQB: AVAI), Stoke Therapeutics (NASDAQ: STOK), Annovis Bio (NYSE: ANVS), Arcutis Biotherapeutics (NASDAQ: ARQT), and Intellia Therapeutics (NASDAQ: NTLA). When
Show less
Read more
Impact Snapshot
Event Time:
STOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STOK alerts
High impacting Stoke Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
STOK
News
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business Wire
- Stoke Therapeutics (STOK) had its "hold (c)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceBusiness Wire
- Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors [Yahoo! Finance]Yahoo! Finance
STOK
Earnings
- 3/16/26 - Beat
STOK
Sec Filings
- 4/7/26 - Form 4
- 4/7/26 - Form 3
- 4/7/26 - Form 8-K
- STOK's page on the SEC website